Skip to main content
. 2021 Aug 24;11:17081. doi: 10.1038/s41598-021-96590-3

Figure 3.

Figure 3

Hepatic CYP2C9 activity (tolbutamide 4′-hydroxylation) (A) and CYP2C9 expression (B) in subjects carrying various CYP2C9 genotypes. CYP2C8*3 carriers and non-genetic factors (CYP2C9 inducer and inhibitor therapy, amoxicillin + clavulanic acid treatment, chronic alcohol consumption) found in clinical reports of the tissue donors are indicated. The median CYP2C9 activity (dotted line) is for the cutoff value between high and low intermediate metabolizers. PM poor metabolizer, IM intermediate metabolizer, EM extensive metabolizer, low low expression, intermediate intermediate expression, high high expression. *P < 0.05; **P < 0.001.